Non Small Cell Lung Cancer: Page 5

FDA clears FoundationOne CDx for Piqray in breast cancer
By LabPulse.com staff writers
Piqray was approved by the FDA in May for second-line treatment in combination with fulvestrant for postmenopausal women and men with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated advanced or metastatic breast cancer.
December 3, 2019
2019 07 27 00 32 8796 Breast Cancer Cell2 400
PathAI reports algorithm on par in PD-L1 immunotherapy studies
By LabPulse.com staff writers
The analyses were conducted with Bristol-Myers Squibb (BMS) and tested the algorithm retrospectively in samples from trials of BMS' programmed cell death ligand 1 (PD-L1) inhibitor nivolumab (Opdivo).
November 6, 2019
2019 11 06 21 24 0710 Path Ai 3 20191106212550
TRACERx data trove helps refine use of blood markers for lung cancer
By Emily Hayes
The multi-institutional Tracking Non-Small Cell Lung Cancer Evolution Through Therapy (TRACERx) translational research program is studying the genetics of 750 lung cancer patients from the time of diagnosis through surgery and either disease relapse or cure. After surgery, the five-year relapse rate in lung cancer ranges from about 20% in patients with stage I disease to 50% at stage III, the investigators noted.
October 8, 2019
2019 10 09 17 32 0093 Dna Cancer Cell 400
Agilent gets green light in China for PD-L1 companion test
By LabPulse.com staff writers
The assay is approved for use as a companion diagnostic with the checkpoint inhibitor pembrolizumab (Keytruda, Merck) as a monotherapy. Clearance covers use in patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) with expression of the PD-L1 biomarker. Keytruda was just approved for this indication in China, following approval for use in combination with chemotherapy.
October 2, 2019
2019 10 03 16 38 3605 Chinese Flag 400
Thermo Fisher seals companion test deal with Lilly
By LabPulse.com staff writers
LOXO-292 is an investigational drug in phase I/II development for cancers with rearranged during transfection (RET) alterations. An estimated 2% of non-small cell lung cancers and 60% of medullary thyroid cancers have RET alterations.
September 8, 2019
2019 09 09 18 41 2711 Cancer Cell Target 400
Thermo Fisher flags data for tumor mutation test
By LabPulse.com staff writers
Tumor mutational burden refers to the number of mutations in cancer cells. It has been emerging as a biomarker for response to checkpoint immunotherapies, including drugs targeting programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1), though its role is still not well understood.
September 5, 2019
2019 09 06 17 09 1120 Cancer Cell Yellow 400
OncoCyte set to buy Razor, reveals plans for lung cancer tests
By LabPulse.com staff writers
The Razor Genomics molecular prognostic assay is designed to assess risk of recurrence following the resection of early-stage, nonsquamous non-small cell lung cancer. The test received a positive initial coverage decision in August from the U.S. Centers for Medicare and Medicaid Services (CMS), which should pave the way for reimbursement.
September 5, 2019
2019 09 05 23 33 2657 Lung General 400
Bio-Techne's prostate cancer test lands FDA breakthrough status
By LabPulse.com staff writers
With the test, a urine sample is evaluated using real-time quantitative reverse transcription polymerase chain reaction (PCR) technology. A higher EPI score is associated with a greater risk for high-grade prostate cancer on biopsy. The test was launched in 2017 in the U.S. by Exosome Diagnostics, which was acquired by Bio-Techne in 2018.
June 19, 2019
2019 06 19 21 28 0345 Prostate 3 D 400
Tumor mutational burden biomarker may not pass muster (again) at ASCO
By Emily Hayes
In one presentation at the meeting, the company will show tumor mutational burden as part of comprehensive genomic profiling was useful for predicting tumor responsiveness to immunotherapy in a study of 3,800 women with three kinds of metastatic breast cancer: HER2-negative (ER-positive/HER2-negative), HER2-amplified, and triple-negative breast cancer. The study outlined the percentage of women with TMB mutations over 10 or 20 mutations per megabase, but it did not correlate genetic status with outcomes.
May 19, 2019
2019 05 20 19 41 9459 Test Tubes Pipette 400
Inivata touts liquid biopsy studies
By LabPulse.com staff writers
The ability of the test of circulating tumor DNA (ctDNA) to detect genetic mutations was evaluated in 264 patients with nonsquamous non-small cell lung cancer (NSCLC) in two multicenter studies. Results were published by Dr. Michael Pritchett and colleagues in the journal on April 25, following their presentation at the World Conference on Lung Cancer in September 2018.
April 25, 2019
2019 04 26 21 45 6845 Lung Lab 400
Previous Page
Page 5 of 5